EGFR and lung adenocarcinoma: Intriguingly, DFS in these IMA patients remained to be significantly associated with KRAS mutation (p=0.016), PI3K pathway alteration (p=0.043), and differentiation grading (p=0.030), but not EGFR mutations (p=0.391) (Table 2), which might be due to the impact of EGFR mutations on lung adenocarcinomas differentiation, as previously described (31).